$BHVN News

Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet

Why Biohaven Stock Was Rocking the Market This Week

SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

Why Is Biohaven Stock Soaring Wednesday?

Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront

Biohaven And Yale Win $4M Judgment Against Avilar And RA Capital Over Willful Misappropriation Of Yale Trade Secret

Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate

Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk

Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?

Biohaven Announces Scientific Leadership Transitions